Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3217]

Research discovery leads to new clinical trial for myelofibrosis patients

Research discovery leads to new clinical trial for myelofibrosis patients

Human-on-a-chip model tests cancer drug efficacy and toxicity for therapeutic index

Human-on-a-chip model tests cancer drug efficacy and toxicity for therapeutic index

$EHA 2019: Acalabrutinib shows remarkable benefit in relapsed or refractory chronic lymphocytic leukaemia$

EHA 2019: Acalabrutinib shows remarkable benefit in relapsed or refractory chronic lymphocytic leukaemia

$EHA 2019: Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in relapsed / refractory multiple myleoma$

EHA 2019: Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related...

EHA 2019: Burning out the T-ALL engine: NADK is a new therapeutic target in T-cell Acute Lymphoblastic Leukaemia

EHA 2019: Burning out the T-ALL engine: NADK is a new therapeutic target in T-cell Acute Lymphoblastic Leukaemia

$EHA 2019: Overcoming the "Don’t Eat Me" signal of refractory lymphomas$

EHA 2019: Overcoming the "Don’t Eat Me" signal of refractory lymphomas

Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy

Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy

Antibody treatment allows transplant of mismatched stem cells, tissues in mice

Antibody treatment allows transplant of mismatched stem cells, tissues in mice

EHA 2019: Phase 3 randomised study of daratumumab plus D-VTd vs VTd in transplant-eligible newly diagnosed multiple myeloma

EHA 2019: Phase 3 randomised study of daratumumab plus D-VTd vs VTd in transplant-eligible newly diagnosed...

EHA 2019: Genomic evidence of residual disease in patients in remission prior to stem cell transplant; fate or opportunity for early intervention?

EHA 2019: Genomic evidence of residual disease in patients in remission prior to stem cell transplant; fate or...

More from ecancer